This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
RARE's Bone Disorder Drug Gets FDA's Breakthrough Therapy Tag
by Zacks Equity Research
Ultragenyx announces that the FDA grants Breakthrough Therapy designation to its investigational osteogenesis imperfecta treatment candidate, setrusumab.
ALNYPositive Net Change CPRXPositive Net Change ANIPNegative Net Change RAREPositive Net Change
biotechnology biotechs gene-editing gene-therapy medical pharmaceuticals
SRRK Stock Soars as Muscle Disease Drug Meets Phase III Study Goal
by Zacks Equity Research
Scholar Rock stock skyrockets as the late-stage study of the investigational therapy, apitegromab, to treat spinal muscular atrophy meets the primary goal.
CPRXPositive Net Change ANIPNegative Net Change BHVNPositive Net Change SRRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
ONCY Stock Up on Regulatory Update From Breast Cancer Program
by Zacks Equity Research
Oncolytics stock soars as the company seeks an accelerated approval pathway for its lead candidate, pelareorep, to treat a breast cancer indication.
AZNPositive Net Change RHHBYPositive Net Change ONCYPositive Net Change ANIPNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Exelixis Gains 20.7% in Three Months: Is This the Right Time to Buy?
by Zacks Equity Research
EXEL stock surges 20.7% on encouraging performance of its lead drug Cabometyx and impressive pipeline progress. We are optimistic about the stock as we believe there is room for growth.
ALNYPositive Net Change BMYPositive Net Change EXELNegative Net Change KRYSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Pacira's Exparel Receives Permanent New Product-Specific J-Code
by Zacks Equity Research
PCRX reports that the CMS has assigned a permanent product-specific J-code for Exparel, which is set to facilitate better insurance coverage for the drug.
PCRXNegative Net Change ANIPNegative Net Change KRYSNegative Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
RARE's Wilson Disease Candidate Betters Standard Therapy in Study
by Zacks Equity Research
Ultragenyx reports superior efficacy of UX701 for Wilson disease compared with standard therapy from the Stage 1 cohorts of its pivotal phase I/II/III study.
ANIPNegative Net Change RAREPositive Net Change KRYSNegative Net Change FULCPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
Do Options Traders Know Something About BioMarin (BMRN) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to BioMarin (BMRN) stock based on the movements in the options market lately.
BMRNNegative Net Change
biotechs medical
GILD Grants Right for HIV PrEP Candidate to Six Generic Companies
by Zacks Equity Research
Gilead signs non-exclusive, royalty-free voluntary licensing agreements with six generic companies to market its investigational medicine, lenacapavir, for HIV Prevention.
GILDNegative Net Change ANIPNegative Net Change KRYSNegative Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
STTK Discontinues Cancer Program, Plans Workforce Cut, Stock Falls
by Zacks Equity Research
Shattuck stock plunges as it discontinues the clinical development of SL-172154 for two blood cancer indications and plans to reduce the workforce by 40%.
BMYPositive Net Change ANIPNegative Net Change FULCPositive Net Change STTKPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Here's Why You Should Add ALNY Stock to Your Portfolio Right Now
by Zacks Equity Research
Alnylam's Amvuttra and Givlaari sales continue to boost revenues. Its ongoing collaboration deals with RHHBY, NVS and REGN are progressing well.
REGNPositive Net Change ALNYPositive Net Change NVSPositive Net Change RHHBYPositive Net Change
biotechnology biotechs medical pharmaceuticals
ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty
by Zacks Equity Research
Arcturus stock gains as the company reports that its sa-mRNA COVID-19 vaccine, ARCT-154, shows superior efficacy compared with treatment with Comirnaty.
PFEPositive Net Change MRNAPositive Net Change ARCTPositive Net Change BNTXPositive Net Change
biotechnology biotechs medical pharmaceuticals vaccines
MRNA Begins Dosing in Pivotal Study on Norovirus Vaccine
by Zacks Equity Research
Moderna doses the first participant in a phase III study evaluating its mRNA norovirus vaccine candidate, mRNA-1403, in the United States.
MRNAPositive Net Change ANIPNegative Net Change KRYSNegative Net Change FULCPositive Net Change
biotechs
SAVA Stock Down on Settling Misleading Alzheimer's Study Data Claims
by Zacks Equity Research
Casava stock falls as the company agrees to pay a cumulative fine exceeding $40 million to settle misleading claims charges brought against it by the SEC.
ANIPNegative Net Change KRYSNegative Net Change SAVANegative Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
ABBV's Newly Added Parkinson's Disease Drug Meets Second Study Goal
by Zacks Equity Research
Data from a late-stage study shows that AbbVie's tavapadon reduced the burden of Parkinson's disease. The drug previously demonstrated efficacy as adjunctive therapy.
ABBVPositive Net Change ADMAPositive Net Change KRYSNegative Net Change BVSPositive Net Change
biotechs medical pharmaceuticals
Bristol Myers Stock Up on FDA Nod for Schizophrenia Treatment
by Zacks Equity Research
The FDA approves BMY's differentiated schizophrenia treatment for adults and broadens its diverse portfolio. Shares gain.
BMYPositive Net Change ABBVPositive Net Change KRYSNegative Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
BMEA Stock Up 9% as FDA Lifts Clinical Hold on 2 Diabetes Studies
by Zacks Equity Research
Biomea stock rises 9% after the FDA lifts clinical hold on two phase I/II studies evaluating the company's lead candidate, BMF-219, for diabetes.
ANIPNegative Net Change KRYSNegative Net Change FULCPositive Net Change BMEAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Biotech Stock Roundup: BHVN, WVE, ZVRA Stocks Up on Updates, BIIB & UCBs Study Data & More
by Zacks Equity Research
Biohaven and Zevra are in the spotlight following positive updates on key candidates.
BIIBPositive Net Change VNDANegative Net Change WVEPositive Net Change BHVNPositive Net Change ZVRAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Pfizer Withdraws Sickle Cell Disease Therapy Oxbryta From Market
by Zacks Equity Research
PFE's decision is based on clinical data, which suggests that the overall benefit of the drug no longer outweighs the risk in the approved patient population.
PFEPositive Net Change ADMAPositive Net Change KRYSNegative Net Change BVSPositive Net Change
biotechs medical pharmaceuticals
AMGN Stock Falls Despite Upbeat Data on Immunology Drugs: Here's Why
by Zacks Equity Research
Though Amgen reported encouraging results on two immunology drugs, Wall Street expresses skepticism as the data fell short when compared to existing treatments.
REGNPositive Net Change SNYPositive Net Change AMGNPositive Net Change ARGXPositive Net Change
biotechs medical pharmaceuticals
CLDX Stock Down Despite Upbeat Long-Term Data From Urticaria Study
by Zacks Equity Research
Celldex stock falls due to safety concerns related to the treatment of urticaria patients with barzolvolimab in a phase II study, despite robust efficacy data.
CLDXPositive Net Change ANIPNegative Net Change KRYSNegative Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
Roche's Lupus Study for Gazyva Meets Primary & Key Secondary Goals
by Zacks Equity Research
RHHBY announces meeting primary and key secondary goals in the late-stage study of its lymphoma drug, Gazyva/Gazyvaro, for treating active lupus nephritis.
RHHBYPositive Net Change ANIPNegative Net Change KRYSNegative Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
TSVT, BMY Discontinue Enrollment in Late-stage Abecma Study
by Zacks Equity Research
2seventy bio and partner BMY decide to stop enrollment in the late-stage study on Abecma due to growth in the newly diagnosed multiple myeloma treatment space.
REGNPositive Net Change BMYPositive Net Change NVOPositive Net Change
biotechnology biotechs cell-therapy medical pharmaceuticals
Incyte Gains 12.7% Year to Date: How Should You Play the Stock?
by Zacks Equity Research
Though INCY's performance in the year so far has been good, increasing competition for Jakafi is a concern. We advise investors to wait and watch before turning positive.
GSKPositive Net Change NVSPositive Net Change INCYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Biogen's Lupus Candidate Meets Key Goals in Phase III Study
by Zacks Equity Research
The phase III PHOENYCS GO study evaluating BIIB and UCB's drug candidate, dapirolizumab pegol, for treating systemic lupus erythematosus meets the primary endpoint.
AZNPositive Net Change GSKPositive Net Change BIIBPositive Net Change ANIPNegative Net Change
biotechs
Eli Lilly Secures Approval for Alzheimer's Drug Kisunla in Japan
by Zacks Equity Research
Japan is the second major market where LLY's Kisunla has been approved. The drug was first approved in the United States in July 2024.
BIIBPositive Net Change LLYPositive Net Change PRTAPositive Net Change SAVANegative Net Change
biotechs medical pharmaceuticals